Aquestive Therapeutics, Inc. announced the appointment of Gary H. Slatko as SVP, Chief Medical Officer (CMO). Dr. Slatko will lead clinical and medical affairs for the company, and is reporting to CEO Keith J. Kendall, effective January 2, 2019. Dr. Slatko's experience includes six years in drug safety regulatory work at the U.S. Food and Drug Administration as a director in the Office of Medication Error Prevention and Risk Management. He also spent over a decade of time as the CMO of ParagonRx.